Table 3.

Results of Cox proportional hazard model analysis of OS for each factor.

	Risk ratio (95% CI)	p value
WHO 2016, grade III	6.46 (0.942–44.4)	0.0575
“Astrocytoma, grade 4”	0.218 (0.00336–14.2)	0.4744
TERTp mutation	5.14 (0.129–204)	0.3838
EGFR amplification	0.709 (0.086–5.84)	0.7493
EGFR gain/amplification	3.04 (0.261–35.4)	0.3749
PDGFRA amplification	2.17 (0.0721–65.5)	0.6549
PTEN homozygous loss	1.65 (0.055–49.4)	0.7730
PTEN loss	5.93 (0.598–58.8)	0.1283
CDK4 gain/amplification	1.16 (0.0755–17.7)	0.9166
MDM2 homozygous loss	1.39 (0.186–10.4)	0.7467
MDM2 alteration	1.47 (0.212–10.2)	0.6978
Age > 40 years	10.9 (0.372–319)	0.1657
After stepwise procedure
PTEN loss	9.75 (2.82–33.7)	0.0003
PTEN homozygous loss	6.97 (1.17–41.5)	0.0329
PDGFR amplification	13.9 (2.58–75.2)	0.0022

The initial candidates (written above the bar) are all factors for which Kaplan–Meier analysis or log-rank testing showed significant results.

CI confidence interval.